Roche "pertuzumab" third indications approved soon


Release time:

2019-04-13

A few days ago, 9 departments including the Guangdong Health Commission, the Provincial Medical Insurance Bureau, and the Provincial Department of Finance jointly issued the ''Key Points for Correcting Unhealthy Practices in the Field of Pharmaceutical Purchase and Sale and Medical Services in Guangdong Province in 2019 ''to carry out special governance in key areas and strictly investigate false Invoicing, tax evasion and other illegal activities, and severely crack down on commercial bribery, money laundering and other illegal crimes. (Cypress Blue)

A few days ago, 9 departments including the Guangdong Health Commission, the Provincial Medical Insurance Bureau, and the Provincial Department of Finance jointly issued the ''Key Points for Correcting Unhealthy Practices in the Field of Pharmaceutical Purchase and Sale and Medical Services in Guangdong Province in 2019 ''to carry out special governance in key areas and strictly investigate false Invoicing, tax evasion and other illegal activities, and severely crack down on commercial bribery, money laundering and other illegal crimes. (Cypress Blue)

| National Health Insurance Consumables Negotiations Begin!

On November 20, the Hainan Provincial Pharmaceutical Centralized Procurement Service Platform announced the "Hainan Province Implementation Plan for the Governance of High-value Medical Consumables", stating that it will gradually implement high-value medical consumables medical insurance access price negotiations to achieve "volume for price". (Cypress Blue Equipment)

Part 2 Observations

| The proposed introduction of state-owned assets to invest in the actual controller of Laimei Pharmaceutical has changed.

On November 25, Chongqing Laimei Pharmaceutical issued an announcement stating that the company's controlling shareholder Qiu Yu and Chongqing Nan'an District Urban Construction and Development (Group) Co., Ltd. negotiated the termination of the Strategic Cooperation Intention Agreement. At the same time, Laimei Pharmaceutical and Guangxi Wuzhou Zhongheng Group Co., Ltd. signed a new "Strategic Cooperation Framework Agreement", entrusting 22.71 percent of the company's shares to Zhongheng Group to exercise the corresponding voting rights. (Sina Medical News)

Part 3 Medicine News

| The first PD-L1 monoclonal antibody in China will be approved soon.

On November 24, AstraZeneca's PD-L1 Durvalumab injection (Imfinzi) application for listing in China was in the "under approval" state. It is expected that it will soon be approved as the first PD-L1 monoclonal antibody drug listed in China for the treatment of inoperable stage III non-small cell lung cancer. (Insight database)